| Name | KR-33493 |
| Description | KR-33493 is a FAS-associated factor 1 (FAF1) inhibitor and can be used in studies about Parkinson's disease. |
| In vitro | Bodyweight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups of either sex are found in hematology, serum biochemistry, and urinalysis. In dogs administrated KR-33493 for 2 weeks, red blood cell count (RBC) value in males is significantly higher at the 1000 mg/kg/day dose than that of the control group (i.e., 6.96±0.323 vs. 6.12±0.418). However, the change of RBC is recovered after the end of the administration period. |
| In vivo | In Sprague-Dawley (SD) rats, KR-33493(500 and 1000 mg/kg; oral) shows no significant changes including Bodyweight changes, hematology, serum biochemistry, and urinalysis. In dogs, red blood cell count value in males is significantly higher at the 1000 mg/kg/day dose with KR-33493 and is recovered after the end of the administration period[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.34 mM), Sonication is recommended.
DMSO : 28 mg/mL (60.82 mM), Sonication is recommended.
|
| Keywords | KR33494 | KR-33493 | KR33493 | KR 33494 | KR 33493 | KM819 | KM 819 | FasL | Fas/FasL | Fas | FAF1 |
| Inhibitors Related | Kaolin | Undecane | Fluorene | Acetylcysteine | Ethyl palmitate | Gum arabic | 1,8-Cineole | Dodecane | 1,4-Naphthoquinone | Tributyrin | Glucosamine | Apremilast |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max |
United States
